조영제 시장 보고서 : 유형별, 모달리티별, 용도별, 투여 경로별, 최종사용자별, 지역별(2025-2033년)

The global contrast media market size reached USD 4.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.7 Billion by 2033, exhibiting a growth rate (CAGR) of 3.55% during 2025-2033. The increasing demand for diagnostic imaging procedures, owing to the growing prevalence of neurological, cancer, and cardiovascular diseases, is one of the key factors stimulating the market growth.

Contrast media, also known as contrast agents, is a group of chemical agents that aid in the characterization of pathology by improving the contrast resolution of an imaging modality. It is administered through injectors via oral, intravascular, and rectal routes. It helps enhance the visibility of the targeted body organs, tissues, and blood vessels during an ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) scan. It also allows radiologists to determine the difference between aberrant and normal tissues of the body in images. As a result, contrast media finds extensive applications in the healthcare industry, especially in radiology, interventional cardiology, diagnostic imaging centers, and ambulatory surgical centers (ASCs) around the world.

Contrast Media Market Trends:

The growing global geriatric population, which is highly susceptible to various chronic medical disorders, represents one of the key factors positively influencing the market. The rising prevalence of cancer, neurological, and cardiovascular diseases are also significantly increasing the demand for diagnostic imaging procedures and contrast media. In line with this, the growing preferences for minimally invasive (MI) medical procedures and surgeries, as they require smaller incisions and cause less postoperative pain, shorter hospital stays, and faster recovery, are offering lucrative growth opportunities to manufacturers. Apart from this, due to a significant rise in medical tourism, the demand for radiopharmaceuticals is increasing across the globe. Furthermore, the advent of digital solutions for precise and effective management of contrast media is driving the demand for contrast media. This, along with the rising focus of several companies on launching innovative products to minimize waste generation during contrast media manufacturing, is strengthening the market growth. Moreover, increasing investments by several leading market players in extensive research and development (R&D) activities are anticipated to propel market growth.

Key Market Segmentation:

Breakup by Type:

• Iodinated Contrast Media
• Gadolinium-based Contrast Media
• Microbubble Contrast Media
• Barium-based Contrast Media

Breakup by Modality:

• X-ray/Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Ultrasound

Breakup by Application:

• Radiology
• Interventional Radiology
• Interventional Cardiology

Breakup by Route of Administration:

• Intravenous/Intrarterial
• Oral Route
• Rectal Route
• Others

Breakup by End User:

• Hospital, Clinics and Ambulatory Surgery Centers
• Diagnostic Imaging Centers

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bayer AG, Beijing Beilu Pharmaceuticals Company Limited, Bracco S.p.A., General Electric Company, Guerbet, iMAX Diagnostic Imaging Limited, J.B. Chemicals & Pharmaceuticals Limited, Jodas Expoim Pvt. Ltd., Lantheus, Nano Therapeutics Pvt Ltd, SANOCHEMIA Pharmazeutika GmbH, TAEJOON PHARM Co. Ltd. and Trivitron Healthcare.

Key Questions Answered in This Report

• 1.What was the size of the global contrast media market in 2024?
• 2.What is the expected growth rate of the global contrast media market during 2025-2033?
• 3.What has been the impact of COVID-19 on the global contrast media market?
• 4.What are the key factors driving the global contrast media market?
• 5.What is the breakup of the global contrast media market based on the type?
• 6.What is the breakup of the global contrast media market based on the modality?
• 7.What is the breakup of the global contrast media market based on the application?
• 8.What is the breakup of the global contrast media market based on the route of administration?
• 9.What are the key regions in the global contrast media market?
• 10.Who are the key players/companies in the global contrast media market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Contrast Media Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Iodinated Contrast Media
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Gadolinium-based Contrast Media
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Microbubble Contrast Media
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Barium-based Contrast Media
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Modality

• 7.1 X-ray/Computed Tomography (CT)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Magnetic Resonance Imaging (MRI)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Ultrasound
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Radiology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Interventional Radiology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Interventional Cardiology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Intravenous/Intrarterial
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Oral Route
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Rectal Route
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospital, Clinics and Ambulatory Surgery Centers
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Diagnostic Imaging Centers
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Bayer AG
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Beijing Beilu Pharmaceuticals Company Limited
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
  • 16.3.3 Bracco S.p.A.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 SWOT Analysis
  • 16.3.4 General Electric Company
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Guerbet
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 iMAX Diagnostic Imaging Limited
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 J.B. Chemicals & Pharmaceuticals Limited
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
  • 16.3.8 Jodas Expoim Pvt. Ltd.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Lantheus
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
  • 16.3.10 Nano Therapeutics Pvt Ltd
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 SANOCHEMIA Pharmazeutika GmbH
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
  • 16.3.12 TAEJOON PHARM Co. Ltd.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
  • 16.3.13 Trivitron Healthcare
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio